Iuvo Imports the Single Largest Cannabinoid Extract Shipment to Europe
News provided by
Share this article
Share this article
POTSDAM, Germany, May 4, 2021 /CNW/ - Iuvo Therapeutics Ltd. ( Iuvo ) is pleased to announce the importation of 20,000 units of full-spectrum extracts derived from non-irradiated GMP certified cannabis flower from partner Cann Group Limited ( Cann Group ). This import is a key milestone for Iuvo to become one of Europe s largest suppliers of cannabinoid-based pharmaceuticals.
Iuvo will be offering two full-spectrum extracts, a high THC and a balanced THC:CBD, both manufactured from premium non-irradiated GMP certified cannabis flower.
Germany continues to be Europe s largest medicinal cannabis market, the demand for cannabinoid extracts has been growing steadily over the last few years increasing from approximately 80,000 prescriptions in 2019 to approximately 200,000 in 2020.
Emyria to focus on initiating and completing pivotal clinical trials for EMD-003 program and advancing EMD-004 program
EMD-003 is being developed to reduce anxiety, depression and stress symptoms while the company is also advancing EMD-004 targeting irritable bowel syndrome. The company secured access to a unique CBD dose product via a partnership with Cann Group
Emyria Ltd (ASX:EMD) will continue its focus on initiating and completing pivotal clinical trials for the EMD-003 program, seeking to register a cannabinoid-based medicine with a unique capsule dose form to reduce symptoms of anxiety, depression and stress.
The data-backed drug development company is also advancing the EMD-004 program targeting irritable bowel syndrome and scoping pipeline expansion therapeutically (with psychedelic-assisted therapy) and geographically with the US Food and Drug Administration (FDA) pathways.
The second Virtual Investor Conference of 2020 gets underway on Thursday. Senior executives from eight companies representing industries ranging from augmented reality to biotech are slated to provide an update on their latest business operations, financials, and take questions from investors.. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to:
This article by Louis O Neill was originally published on The Green Fund, and appears here with permission.
ECS Botanics is planning to expand its Tasmanian operations by a hundredfold as it lodges plans with the Office of Drug Control to upsize its cultivation area from 2,500 sqm to 320,000 sqm.
ECS Botanics (ASX:ECS) recently announced it had lodged plans with the Office of Drug Control (ODC) to expand its Tasmanian operations, again building on its current position as the ASX s largest and lowest-cost producer of medicinal cannabis in Australia.
The company will be focusing on producing low-THC cannabis in Tasmania, most of which will be grown outdoors, to be used in the creation of CBD products.
Matt Cantelo in the cannabis greenhouse.
Business by Glen Norris
Premium Content
Subscriber only One of the world s biggest medicinal cannabis production facilities is planned for Queensland amid surging demand for the pain relief medicine. The $400m growing and processing facility near the regional city of Towoomba could produce 500 tonnes of the medicine each year and generate 1000 jobs. The project follows the merger of Byron Bay-based Australian Natural Therapeutics Group (ANTG) and Toronto s Canadian Asterion Cannabis. Construction of the 75ha complex adjacent to the Wellcamp Airport west of Toowoomba is scheduled to begin in the next few months, with the first 10ha glasshouse and manufacturing facility operating by the end of next year.